Luigi Naldini
Auto-generated profile, based on publicly available information

Luigi Naldini

San Raffaele Telethon Institute for Gene Therapy (SR-Tiget), IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy; Vita-Salute San Raffaele University, 20132 Milan, Italy

Research Focus & Metrics

Academic Career Length

47Years (1980-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 April 1996 in Science
Verified
Journal Article
Closed access
PDF file
LNLuigi Naldini
Luigi Naldini
UBUlrike Blömer
Ulrike Blömer
PGPhilippe Gallay
Philippe Gallay
DODaniel Ory
Daniel Ory
RMRichard Mulligan
Richard Mulligan
DTDidier Trono
Didier Trono
A retroviral vector system based on the human immunodeficiency virus (HIV) was developed that, in contrast to a murine leukemia virus-based counterpart, transduced heterologous sequences into HeLa cells and rat fibroblasts blocked in the cell cycle, as well as into human primary macrophages. Additionally, the HIV vector could mediate stable in vivo gene transfer into terminally differentiated neurons. The ability of HIV-based viral vectors to deliver genes in vivo into nondividing cells could increase the applicability of retroviral vectors in human gene therapy.

1 November 1998 in Journal of Virology
Verified
Journal Article
Closed access
TDTom Dull
Tom Dull
RZRomain Zufferey
Romain Zufferey
MKMichael Kelly
Michael Kelly
RMR. J. Mandel
R. J. Mandel
MNMinh Nguyen
Minh Nguyen
LNLuigi Naldini
Luigi Naldini
Vectors derived from human immunodeficiency virus (HIV) are highly efficient vehicles for in vivo gene delivery. However, their biosafety is of major concern. Here we exploit the complexity of the HIV genome to provide lentivirus vectors with novel biosafety features. In addition to the structural genes, HIV contains two regulatory genes, tat and rev, that are essential for HIV replication, and four accessory genes that encode critical virulence factors. We previously reported that the HIV type 1 accessory open reading frames are dispensable for efficient gene transduction by a lentivirus vector. We now demonstrate that the requirement for the tat gene can be offset by placing constitutive promoters upstream of the vector transcript. Vectors generated from constructs containing such a chimeric long terminal repeat (LTR) transduced neurons in vivo at very high efficiency, whether or not they were produced in the presence of Tat. When the rev gene was also deleted from the packaging construct, expression of gag and pol was strictly dependent on Rev complementation in trans. By the combined use of a separate nonoverlapping Rev expression plasmid and a 5′ LTR chimeric transfer construct, we achieved optimal yields of vector of high transducing efficiency (up to 107transducing units [TU]/ml and 104 TU/ng of p24). This third-generation lentivirus vector uses only a fractional set of HIV genes: gag, pol, and rev. Moreover, the HIV-derived constructs, and any recombinant between them, are contingent on upstream elements and trans complementation for expression and thus are nonfunctional outside of the vector producer cells. This split-genome, conditional packaging system is based on existing viral sequences and acts as a built-in device against the generation of productive recombinants. While the actual biosafety of the vector will ultimately be proven in vivo, the improved design presented here should facilitate testing of lentivirus vectors.

1 September 1997 in Nature Biotechnology
Verified
Journal Article
Closed access
PDF file
RZRomain Zufferey
Romain Zufferey
DNDea Nagy
Dea Nagy
RMRon J. Mandel
Ron J. Mandel
LNLuigi Naldini
Luigi Naldini
DTDidier Trono
Didier Trono

15 October 1996 in Proceedings of the National Academy of Sciences of the United States of America
Verified
Journal Article
Closed access
PDF file
LNL Naldini
L Naldini
UBU Blömer
U Blömer
FGF H Gage
F H Gage
DTD Trono
D Trono
IVI M Verma
I M Verma
We describe the construction of a safe, replication-defective and efficient lentiviral vector suitable for in vivo gene delivery. The reverse transcription of the vector was found to be a rate-limiting step; therefore, promoting the reaction inside the vector particles before delivery significantly enhanced the efficiency of gene transfer. After injection into the brain of adult rats, sustained long-term expression of the transgene was obtained in the absence of detectable pathology. A high proportion of the neurons in the areas surrounding the injection sites of the vector expressed the transduced beta-galactosidase gene. This pattern was invariant in animals sacrificed several months after a single administration of the vector. Transduction occurs by integration of the vector genome, as it was abolished by a single amino acid substitution in the catalytic site of the integrase protein incorporated in the vector. Development of clinically acceptable derivatives of the lentiviral vector may thus enable the sustained delivery of significant amounts of a therapeutic gene product in a wide variety of somatic tissues.

1 September 2005 in Cancer Cell
Verified
Journal Article
Closed access
MPMichele De Palma
Michele De Palma
MARY ANNA VENNERIMARY ANNA VENNERI
MARY ANNA VENNERI
RGRossella Galli
Rossella Galli
LSLucia Sergi Sergi
Lucia Sergi Sergi
LPLetterio S. Politi
Letterio S. Politi
LNLuigi Naldini
Luigi Naldini

14 October 2015 in Nature
Verified
Journal Article
Closed access
PDF file
LNLuigi Naldini
Luigi Naldini